Emergent BioSolutions (EBS) Reports Q3 results; updates guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $7.02 +4.00%
Revenue Growth %: -45.6%
Financial Fact:
Weighted-average number of shares - basic: 40.47M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: -45.6%
Financial Fact:
Weighted-average number of shares - basic: 40.47M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 Revenue for the quarter at $271 million versus the consensus estimate of $237.43 million.
GUIDANCE:
Emergent BioSolutions sees FY2023 revenue of $1-1.1 billion, versus the consensus of $1.04 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Intuit holds investor day, reaffirms fiscal 2027 guidance
- Investec Double Upgrades Supreme Industries (SI:IN) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
